Cathy Eng, MD, FACP | Authors

Articles

Ongoing Clinical Trials in BRAF-Mutant CRC

January 15, 2018

Cathy Eng, MD, FACP, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses ongoing clinical trials in the BRAF-mutant colorectal cancer patient population.

Choosing Between TAS-102 and Regorafenib in Colorectal Cancer

November 30, 2017

Cathy Eng, MD, FACP, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses choosing between TAS-102 (Lonsurf) and regorafenib (Stivarga) in colorectal cancer.

Dr. Cathy Eng on Bevacizumab Plus FOLFOXIRI for Patients With mCRC.

January 22, 2016

Cathy Eng, MD, FACP, medical oncologist, The University of Texas MD Anderson Cancer Center, discusses the combination of bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as a treatment for patients with metastatic colorectal cancer (mCRC).

Dr. Cathy Eng on Bevacizumab Plus FOLFOXIRI for Patients With mCRC

January 22, 2016

Cathy Eng, MD, FACP, medical oncologist, The University of Texas MD Anderson Cancer Center, discusses the combination of bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as a treatment for patients with metastatic colorectal cancer (mCRC).